<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38061134</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Inhibition of SARS-CoV-2 infection and replication by Petasites hybridus CO2-extract (Ze 339).</ArticleTitle><Pagination><StartPage>115959</StartPage><MedlinePgn>115959</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2023.115959</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(23)01757-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The intensified search for low-threshold herbal anti-viral drugs would be of great advantage in prevention of early stages of infection. Since the SARS-CoV-2 Omicron variant has prevailed in western countries, the course has only been mild, but there are still no widely available drugs that can alleviate or shorten disease progression and counteract the development of Long-COVID. This study aimed to investigate the antiviral effects of a CO<sub>2</sub>-extract from Petasites hybridus (Ze 339).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the infection and replication rate of SARS-CoV-2 in primary normal human bronchial epithelial cells (NHBEs) using a GFP-expressing version of the wild-type SARS-CoV-2 virus and live cell imaging. Upon infection with a clinical isolate of the Omicron variant, viral RNA content was quantified, and plaque assays were performed. In addition, the human transcriptome was analyzed after 4- and 24-hours post infection using whole genome microarrays.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ze 339 had a protective effect on primary airway epithelial cells during SARS-CoV-2 infection and impeded SARS-CoV-2 infection and replication in NHBE. Notably, Ze 339 inhibited the expression of infection-induced IFNA10 by 8.6-fold (p&#xa0;&lt;&#xa0;0.05) and additionally reduced a wide range of other interferons (IFNA6, IFNA7, IFNA8, IFNA21, IFNE, IFNW1).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Thereby, Ze 339 attenuated epithelial infection by SARS-CoV-2 and modeled the IFN response. In conclusion, this study highlights Ze 339 as a potential treatment option for COVID-19 that limits infection-associated cell intrinsic immune responses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jakwerth</LastName><ForeName>Constanze A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Center of Allergy and Environment (ZAUM), Technical Universit&#xe4;t and Helmholtz Center Munich, Munich, Germany; German Center for Lung Research (DZL), Germany. Electronic address: constanze.jakwerth@tum.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grass</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Technical University of Munich, School of Medicine, Institute of Virology, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erb</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Allergy and Environment (ZAUM), Technical Universit&#xe4;t and Helmholtz Center Munich, Munich, Germany; German Center for Lung Research (DZL), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pichlmair</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Technical University of Munich, School of Medicine, Institute of Virology, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonen</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Department, Max Zeller Soehne AG, Romanshorn, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butterweck</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Medical Department, Max Zeller Soehne AG, Romanshorn, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt-Weber</LastName><ForeName>Carsten B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Center of Allergy and Environment (ZAUM), Technical Universit&#xe4;t and Helmholtz Center Munich, Munich, Germany; German Center for Lung Research (DZL), Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C476335">Ze 339</NameOfSubstance></Chemical><Chemical><RegistryNumber>142M471B3J</RegistryNumber><NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036901" MajorTopicYN="Y">Petasites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002245" MajorTopicYN="N">Carbon Dioxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral therapeutic</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Interferons (IFN)</Keyword><Keyword MajorTopicYN="N">Omicron variant</Keyword><Keyword MajorTopicYN="N">Petasites hybridus</Keyword><Keyword MajorTopicYN="N">Primary normal human bronchial epithelial cells (NHBEs)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Jakwerth reports grants from Federal Ministry of Education and Research (BMBF) for the German Center for Lung Research, (DZL) and for BMBF ESCAPE consortium, during the conduct of the study; grants from Federal German Ministry of Education and Research (BMBF ABROGATE), grants from European Institute of Technology, grants and personal fees from Zeller, outside the submitted work. In addition, Dr. Jakwerth has a patent EP3909646 issued. Dr. Georg Boonen and Prof. Dr. Veronika Butterweck are employees of Max Zeller Soehne AG, CH-8590 Romanshorn, Switzerland, the manufacturer of Ze 339. Prof. Dr. Schmidt-Weber reports grants from Federal Ministry of Education and Research (BMBF) for the German Center for Lung Research, (DZL) and for BMBF ESCAPE consortium, grants from German Research Foundation (DFG Grant No. 398577603), grants from Bavarian State Office for Health and Food Safety (K1&#x2013;2497-GLB-20-V4), during the conduct of the study. He received personal fees from Sanofi and Leti Pharma, FNF, grants from Federal German Ministry of Education and Research (BMBF ABROGATE), grants from European Institute of Technology, grants from Zeller AG, outside the submitted work. In addition, Prof. Dr. Schmidt-Weber has a patent EP3909646 issued. Anna Erb, Dr. Vincent Grass and Prof. Dr. Andreas Pichlmair have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38061134</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2023.115959</ArticleId><ArticleId IdType="pii">S0753-3322(23)01757-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>